“Precision Medicine market set to grow to $97bn by 2024” says new Visiongain report

30 May 2019
Pharma

Visiongain has launched a new pharma report Global Precision Medicine Market Forecast 2019-2029: Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases.

The global precision medicine market is expected to grow at an estimated CAGR of 10.5% from 2018 to 2029. In the precision medicine market, the Diagnostic Tool companies segment is dominating the global market and accounted for $23.36 billion in 2018 due to the development of large number of diagnostic and genetic tests.

The lead analyst of the report commented "The deep understanding of precision medicine applications within the context of e-Health will be essential to align the benefits of mobile technologies within the broader framework of health and e-Health priorities. Faulty regulations for healthcare providers is affecting the precision medicine market as they are hampering the innovation and technological developments.

One of the reasons for the hampered growth of the precision medicine market is the lack of knowledge and awareness about the possible applications of precision medicine application and public health outcomes among the end users. This challenge highlighted the need for evaluation of precision medicine related educational programs across a range of target groups."

Leading companies featured in the report include Abbott, Danaher Corporation, GE Healthcare, GlaxoSmithKline, Illumina, Inc., Johnson & Johnson, Laboratory Corporation of America Holdings and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on + 44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever